BRPI0607140A2 - compound, use of the compound and / or use of a pharmaceutically acceptable salt, lactone or prodrug of said compound, pharmaceutical composition, pharmaceutical kit, method for stimulating uptake of glucose by muscle cells and / or adipocyte cells, method for stimulating insulin secretion by pancreatic cells (beta) cells and method for treating a mammal that has a disorder of carbohydrate or lipid metabolism - Google Patents

compound, use of the compound and / or use of a pharmaceutically acceptable salt, lactone or prodrug of said compound, pharmaceutical composition, pharmaceutical kit, method for stimulating uptake of glucose by muscle cells and / or adipocyte cells, method for stimulating insulin secretion by pancreatic cells (beta) cells and method for treating a mammal that has a disorder of carbohydrate or lipid metabolism

Info

Publication number
BRPI0607140A2
BRPI0607140A2 BRPI0607140-6A BRPI0607140A BRPI0607140A2 BR PI0607140 A2 BRPI0607140 A2 BR PI0607140A2 BR PI0607140 A BRPI0607140 A BR PI0607140A BR PI0607140 A2 BRPI0607140 A2 BR PI0607140A2
Authority
BR
Brazil
Prior art keywords
compound
cells
stimulating
carbohydrate
pharmaceutically acceptable
Prior art date
Application number
BRPI0607140-6A
Other languages
Portuguese (pt)
Inventor
Claude Coquelet
Charles Mioskowski
Alain Wagner
Original Assignee
Innodia Inc
Centre Nat Rech Scient Cnrs
Univ Pasteur Strasbourg I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innodia Inc, Centre Nat Rech Scient Cnrs, Univ Pasteur Strasbourg I filed Critical Innodia Inc
Publication of BRPI0607140A2 publication Critical patent/BRPI0607140A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms

Abstract

COMPOSTO, USO DO COMPOSTO E/OU USO DE UM SAL, LACTONA OU PRó-MEDICAMENTO FARMACEUTICAMENTE ACEITáVEL DO DITO COMPOSTO, COMPOSIçãO FARMACêUTICA, KIT FARMACêUTICO, MéTODO PARA ESTIMULAR A CAPTAçãO DE GLICOSE PELAS CéLULAS MUSCULARES E/OU CéLULAS DE ADIPóCITO, MéTODO PARA ESTIMULAR A SECREçãO DE INSULINA PELAS CéLULAS PANCREáTICAS CéLULAS-13 E MéTODO PARA O TRATAMENTO DE UM MAMìFERO QUE TEM UM DISTúRBIO DO METABOLISMO DE CARBOIDRATOS OU DE LIPìDIOS. A invenção refere-se aos isómeros configuracionais de 4-hidróxi isoleucina e às lactonas, sais farmaceuticamente aceitáveis e pró-medicamentos dos mesmos, aos processos para a sua preparação e às composições farmacêuticas que compreendem os mesmos. Os isómeros da invenção exibem atividade insulinotrópica e, desse modo, podem ser úteis para a prevenção e o tratamento dos distúrbios do metabolismo de carboidratos ou de lipídios, incluindo o diabetes meilitus (diabetes tipo 1 e tipo 2), pré-diabetes e a Síndrome Metabólica.COMPOUND, USE OF COMPOUND AND / OR USE OF A PHARMACEUTICALLY ACCEPTABLE SALT, LACTONA OR PRODUCT OF COMPOUND, PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL KIT, METHOD FOR STIMULATING CELLULULAR CELLULLE OR CELLULLE CELLULATION PANCREATIC CELL-13 CELLS AND METHOD FOR THE TREATMENT OF A MAMMIFER THAT HAS A DISORDER OF CARBOHYDRATE OR LIPID METABOLISM. The invention relates to configurational isomers of 4-hydroxy isoleucine and to lactones, pharmaceutically acceptable salts and prodrugs thereof, processes for their preparation and pharmaceutical compositions comprising them. The isomers of the invention exhibit insulinotropic activity and thus may be useful for the prevention and treatment of carbohydrate or lipid metabolism disorders, including diabetes meilitus (type 1 and type 2 diabetes), prediabetes, and the syndrome. Metabolic

BRPI0607140-6A 2005-02-18 2006-02-17 compound, use of the compound and / or use of a pharmaceutically acceptable salt, lactone or prodrug of said compound, pharmaceutical composition, pharmaceutical kit, method for stimulating uptake of glucose by muscle cells and / or adipocyte cells, method for stimulating insulin secretion by pancreatic cells (beta) cells and method for treating a mammal that has a disorder of carbohydrate or lipid metabolism BRPI0607140A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65441305P 2005-02-18 2005-02-18
PCT/IB2006/001758 WO2006117696A2 (en) 2005-02-18 2006-02-17 Diastereoisomers of 4-hydroxyisoleucine and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0607140A2 true BRPI0607140A2 (en) 2009-08-11

Family

ID=37086084

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607140-6A BRPI0607140A2 (en) 2005-02-18 2006-02-17 compound, use of the compound and / or use of a pharmaceutically acceptable salt, lactone or prodrug of said compound, pharmaceutical composition, pharmaceutical kit, method for stimulating uptake of glucose by muscle cells and / or adipocyte cells, method for stimulating insulin secretion by pancreatic cells (beta) cells and method for treating a mammal that has a disorder of carbohydrate or lipid metabolism

Country Status (8)

Country Link
EP (1) EP1853552A2 (en)
JP (1) JP2008530198A (en)
CN (1) CN101128418A (en)
AU (1) AU2006242851A1 (en)
BR (1) BRPI0607140A2 (en)
CA (1) CA2598491A1 (en)
MX (1) MX2007009985A (en)
WO (1) WO2006117696A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131836A2 (en) * 2005-03-22 2006-12-14 Innodia Inc. Compounds and compositions for use in the prevention and treatment of obesity and related syndromes
WO2008154743A1 (en) * 2007-06-19 2008-12-24 Innodia Inc. Methods for the synthesis of 4-hydroxyisoleucine, stereoisomers and analogs thereof
WO2009085180A1 (en) * 2007-12-20 2009-07-09 The Feinstein Institute For Medical Research Treatment of sepsis and inhibition of mif by d-t4
JP6800968B2 (en) 2015-10-23 2020-12-16 ナビター ファーマシューティカルズ， インコーポレイテッド Sestrin-GATOR2 interaction modulator and its use
WO2018200625A1 (en) 2017-04-26 2018-11-01 Navitor Pharmaceuticals, Inc. Modulators of sestrin-gator2 interaction and uses thereof
AU2019364542A1 (en) 2018-10-24 2021-06-10 Navitor Pharmaceuticals, Inc. Polymorphic compounds and uses thereof
US11723890B2 (en) 2019-11-01 2023-08-15 Navitor Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator
CN112089710B (en) * 2020-08-07 2022-04-01 郑州大学 Application of 4-hydroxyisoleucine in preparation of antitumor drugs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2797767B1 (en) * 1999-08-27 2002-06-14 Centre Nat Rech Scient USE OF AMINO ACIDS FOR THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF INSULIN RESISTANCES
US20070004623A1 (en) * 2003-10-27 2007-01-04 Innodia Inc. Use of hydroxylated amino acids for treating diabetes
EP1657236A1 (en) * 2004-11-10 2006-05-17 Centre National De La Recherche Scientifique (Cnrs) Method for preparing diastereoisomers of 4-hydroxy isoleucine

Also Published As

Publication number Publication date
MX2007009985A (en) 2008-03-11
CN101128418A (en) 2008-02-20
CA2598491A1 (en) 2006-11-09
WO2006117696A2 (en) 2006-11-09
AU2006242851A1 (en) 2006-11-09
EP1853552A2 (en) 2007-11-14
WO2006117696A3 (en) 2007-01-25
JP2008530198A (en) 2008-08-07

Similar Documents

Publication Publication Date Title
BRPI0607156A2 (en) compound, pharmaceutical composition, use of the compound, pharmaceutical kit, method for stimulating glucose uptake by muscle cells and / or adipocyte cell and method for stimulating pancreatic secretion
BRPI0607140A2 (en) compound, use of the compound and / or use of a pharmaceutically acceptable salt, lactone or prodrug of said compound, pharmaceutical composition, pharmaceutical kit, method for stimulating uptake of glucose by muscle cells and / or adipocyte cells, method for stimulating insulin secretion by pancreatic cells (beta) cells and method for treating a mammal that has a disorder of carbohydrate or lipid metabolism
AU2020201457B2 (en) Compositions and methods for managing or improving bone disorders, cartilage disorders, or both
KR102396831B1 (en) Compositions and methods for joint
Li et al. Antihyperglycemic and antihyperlipidemic action of cinnamaldehyde in C57BLKS/J db/db mice
Li et al. Gastrodin and isorhynchophylline synergistically inhibit MPP+-induced oxidative stress in SH-SY5Y cells by targeting ERK1/2 and GSK-3β pathways: involvement of Nrf2 nuclear translocation
ECSP088139A (en) METHODS TO PREVENT AND TREAT METABOLIC AND NEW DISORDERS DERIVED FROM PIRAZOL-O-GLUCOSIDE
UA100384C2 (en) Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative
BRPI0516454A (en) compound, process for preparing a compound, pharmaceutical composition comprising it, its use, method for treating and prophylaxis of diseases, and type II diabetes
BRPI0507189A (en) combined use of a glp-1 agonist and gastrin compounds
BRPI0718596B8 (en) pharmaceutical compositions for combination therapy with sglt-2 and metformin inhibitors
BR112013020620A2 (en) 4-hydroxybutyric acid analogs
BRPI1015120A2 (en) lipid compound, pharmaceutical and lipid compositions, methods of producing lipid compound and for preventing or treating diseases and uses of at least one compound
BRPI0618552B8 (en) pyrimidine derivative compounds linked to oxygen, pharmaceutical composition that includes said compounds, method of synthesis of the compounds and therapeutic uses thereof
WO2008124505A3 (en) Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
NO20054408L (en) 3 (2-Phenyl-oxazol-4-yl-methoxy) -cyclohexylmethoxyacetic acid derivatives and similar compounds as PPAR modulators for the treatment of type 2 diabetes and arteriosclerosis
Wu et al. Anti-inflammatory effect of a polyphenol-enriched fraction from Acalypha wilkesiana on lipopolysaccharide-stimulated RAW 264.7 macrophages and acetaminophen-induced liver injury in mice
BRPI0611550A2 (en) use of a compound selected from the group consisting of 4-hydroxy isoleucine isomers, 4-hydroxy isoleucine analogs, and lactones, salts, metabolites, solvates and / or pharmaceutically acceptable prodrugs of said isomers and analogs, compound, pharmaceutical kit , pharmaceutical composition, use of the compound and kit with compound
Chmiel-Perzyńska et al. Novel aspect of ketone action: β-hydroxybutyrate increases brain synthesis of kynurenic acid in vitro
BR112015001056A2 (en) compound, pharmaceutical composition, methods for the treatment of aldosterone-mediated disorders, for the treatment of disease or a condition, for the treatment of metabolic syndrome, for the treatment of a physiological or pathological disease, and for the treatment of chronic kidney disease, insufficiency renal disease or diabetic nephropathy
Xiong et al. Intermittent fasting alleviates type 1 diabetes-induced cognitive dysfunction by improving the frontal cortical metabolic disorder
Kulkarni et al. Antidiabetic potential of Rourea minor (Gaertn.) root in streptozotocin—induced diabetic rats
BRPI0602179A (en) pharmaceutical composition comprising cyclobenzaprine and aceclofenac in combination
Yousaf et al. Hypolipidemic effect of extra virgin olive oil in diabetic rats
BR112021026561A2 (en) Use of a pharmaceutical composition in the manufacture of a medicament for the prevention or treatment of liver disease

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired